A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 2 entries
    • Study completion pushed from Jun 2026 to Jun 2027
    • Eligibility criteria expanded, about 20 words
  2. Re-verified, no change to tracked fieldsv10
  3. Study completion date: Jun 2025 to Jun 2026v9
  4. Results first posted: Feb 18, 2025
    • Primary endpoints revised (2)
    • Primary completion date changed from estimate of Jun 2025 to Aug 30, 2023
    v8
  5. Primary and study completion dates: Jun 2024 to Jun 2025v7
Show 5 earlier versionsHide 5 earlier versions
  1. 2 versions Re-verified since May 26, 2023, no change to tracked fieldsv5-v6
  2. Primary and study completion dates: Jun 2023 to Jun 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 23
    • Site details revised at 7 of 7 sites
    v4
  3. Re-verified, no change to tracked fieldsv3
  4. Eligibility criteria expanded, about 53 wordsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will test whether a plant-based diet is practical (feasible) for overweight people with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). The researchers will decide how practical the diet is by looking at how much weight participants lose and how well they are able to stick to the diet. The researchers will also determine whether the diet is effective in preventing multiple myeloma in participants. In addition, they will look at how safe the plant-based diet is for participants, and see if the diet affects participants' quality of life.
Trial Details
NCT Number NCT04920084
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions
(from sponsor)		 Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Related terms Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Enrollment 23 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov